logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12054475 B1

PDFFull Text
Date of Patent:
Aug. 06, 2024

Filed:

Oct. 17, 2023

Substituted heterocycles as aldehyde dehydrogenase inhibitors

Applicants:

Kayothera Inc., Seattle, WA (US);

The Trustees of Princeton University, Princeton, NJ (US);

Inventors:

Mark Esposito, Cazenovia, NY (US);

John Proudfoot, Newtown, CT (US);

Yibin Kang, Princeton, NJ (US);

John Piwinski, Lebanon, NJ (US);

Assignees:

KayoThera Inc., Seattle, WA (US);

The Trustees of Princeton University, Princeton, NJ (US);

Attorney:

COOLEY LLP

Primary Examiner:

Douglas M Willis

Int. Cl.
CPC ...
A61K 31/4709 (2006.01); A61K 31/473 (2006.01); A61K 31/4738 (2006.01); A61P 35/00 (2006.01); C07D 215/227 (2006.01); C07D 215/50 (2006.01); C07D 401/12 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); C07D 471/04 (2006.01); C07D 471/14 (2006.01); C07D 491/048 (2006.01); C07D 498/04 (2006.01); C07D 513/04 (2006.01);
U.S. Cl.
CPC ...
C07D 401/12 (2013.01); A61P 35/00 (2018.01); C07D 215/50 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01); C07D 491/048 (2013.01); C07D 498/04 (2013.01); C07D 513/04 (2013.01);
Abstract

Provided herein are novel heterocyclic compounds, for example, compounds of Formula (IV-C). Also provided herein are pharmaceutical compositions comprising the compounds and methods of using the same, for example, in inhibiting aldehyde dehydrogenases, retinoid pathway activation, and/or for treating various cancers, cancer metastasis, type 2 diabetes, pulmonary arterial hypertension (PAH) or neointimal hyperplasia (NIH) or as a male contraceptive.

Find Patent Forward Citations

Loading…